Opus Genetics (IRD) Interest & Investment Income (2010 - 2020)
Opus Genetics (IRD) reported Interest & Investment Income of $1774.0 for Q3 2020, down 97.74% year-over-year from $78534.0 in Q4 2019, and down 70.64% on a QoQ basis from $6042.0 in Q2 2020.
Opus Genetics (IRD) has 11 years of Interest & Investment Income data on file, last reported at $1774.0 in Q3 2020.
- Quarterly Interest & Investment Income fell 97.74% year-over-year to $1774.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $99365.0 (down 68.21% YoY) and the FY2019 annual result came in at $313700.0, up 23.34% from the prior year.
- Interest & Investment Income fell to $1774.0 in Q3 2020 per IRD's latest filing, from $6042.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $96650.0 in Q2 2019 and bottomed at $1774.0 in Q3 2020.
- The 5-year median for Interest & Investment Income is $55153.0 (2018), against an average of $49255.1.
- The widest annual swing landed in 2018, when Interest & Investment Income soared 138.19%; it then sank 97.74% in 2020.
- Tracing IRD's Interest & Investment Income over 5 years: stood at $34681.0 in 2016, then soared by 106.67% to $71674.0 in 2017, then retreated by 21.89% to $55982.0 in 2018, then advanced by 2.05% to $57131.0 in 2019, then slumped by 96.89% to $1774.0 in 2020.
- Per Business Quant, the three latest IRD Interest & Investment Income figures stand at $1774.0 (Q3 2020), $6042.0 (Q2 2020), and $34418.0 (Q1 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 1,774.00 |
| Jun 30, 2020 | 6,042.00 |
| Mar 31, 2020 | 34,418.00 |
| Dec 31, 2019 | 57,131.00 |
| Sep 30, 2019 | 78,534.00 |
| Jun 30, 2019 | 96,650.00 |
| Mar 31, 2019 | 81,385.00 |
| Dec 31, 2018 | 55,982.00 |
| Sep 30, 2018 | 55,153.00 |
| Jun 30, 2018 | 67,473.00 |
| Mar 31, 2018 | 75,736.00 |
| Dec 31, 2017 | 71,674.00 |
| Sep 30, 2017 | 60,750.00 |
| Jun 30, 2017 | 42,782.00 |
| Mar 31, 2017 | 31,797.00 |
| Dec 31, 2016 | 34,681.00 |
| Sep 30, 2016 | 26,145.00 |
| Jun 30, 2016 | 28,868.00 |
| Mar 31, 2016 | 28,871.00 |
| Dec 31, 2015 | 21,943.00 |
| Sep 30, 2015 | 23,724.00 |
| Jun 30, 2015 | 27,020.00 |
| Mar 31, 2015 | 30,582.00 |
| Dec 31, 2014 | 28,717.00 |
| Sep 30, 2014 | 34,864.00 |
| Jun 30, 2014 | 38,035.00 |
| Mar 31, 2014 | 32,291.00 |
| Dec 31, 2013 | 14,536.00 |
| Sep 30, 2013 | 13,293.00 |
| Jun 30, 2013 | 11,433.00 |
| Mar 31, 2013 | 10,018.00 |
| Dec 31, 2012 | 3,908.00 |
| Sep 30, 2012 | 6,641.00 |
| Jun 30, 2012 | 4,294.00 |
| Mar 31, 2012 | 6,249.00 |
| Dec 31, 2011 | 8,326.00 |
| Sep 30, 2011 | 19,592.00 |
| Jun 30, 2011 | 38,849.00 |
| Mar 31, 2011 | 42,471.00 |
| Dec 31, 2010 | 35,569.00 |
| Sep 30, 2010 | 49,418.00 |
| Jun 30, 2010 | 26,267.00 |